PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

Inclusion Criteria: 1. Age 18-75 years old, gender is not limited; 2. Patients with esophageal squamous cell carcinoma with neoadjuvant immunotherapy combined with chemotherapy (radiotherapy was not planned during the study period); 3. Thoracic esophageal squamous cell carcinoma patients with residual pathologic primary site and lymph node positive (ypT1-4aN0M0) after surgery (8th UICC-TNM stage); 4. The operation was radical resection; 5. Physical status ECOG 0 \~ 1 score; 6. No local recurrence or distant metastasis was found in the examination before postoperative adjuvant treatment; 7. There were no contraindications of chemotherapy or immunotherapy in the evaluation of various organ functions; 8. Understand and sign the informed consent. Exclusion Criteria: 1. Had malignant tumors other than esophageal cancer within 5 years prior to admission (cured localized tumors were not excluded, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ, etc.); Prostate cancer patients who received hormone therapy and obtained DFS for more than 5 years were not excluded). 2. Prior history of interstitial lung disease, or pneumonia requiring steroid treatment when enrolled; 3. Receiving systemic steroid therapy (more than 10mg of prednisone per day or equivalent) or other immunosuppressant within 2 weeks prior to randomization; 4. People who have been severely allergic to chemotherapy drugs (fluorouracil) or any monoclonal antibody; 5. Patients with active autoimmune diseases; 6. Patients with active hepatitis 7. According to the judgment of the researcher, there are other circumstances that are not suitable for participation in this study.